Themis and ZIKAVAX consortium announce initiation of Phase 1 Zika vaccine trial1. October 2019|In Portfolio News|By eazee-designstudioThemis announced today the initiation of a Phase 1 clinical trial of a second-generation Zika vaccine. The vaccine candidate is based on Themis’ proprietary measles vector platform, which includes exclusively licensed technology from Institut Pasteur. It was initially developed by Institut Pasteur as part of the ZIKAVAX consortium, coordinated by the European Vaccine Initiative (EVI) and including Themis and the Commissariat à l’énergie atomique et aux énergies alternatives (CEA). PrevNext
